Additional Trials | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab - Sally Thirkettle, Joanne Russell, Sarah Wilson, Tasneem Ganijee, Samar Kulkarni, Jim Cavet, Phillip J Monaghan,
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
PDF) Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease | Leukemia
Case 966-- Clinical Chemistry Case
Multiple Myeloma Resources | DARZALEX® (daratumumab) & DARZALEX FASPRO® ( daratumumab and hyaluronidase-fihj) HCP
SEBIA HYDRASHIFT 2/4 daratumumab test kit | Medical Supply Company
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
Anti Daratumumab Antibody, clone AbD44786ia | Bio-Rad
Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports
Siba El Hussein, MD on Twitter: "Daratumumab, an anti-CD38 IgG Kappa antibody, can cause light chain restriction in hematogones, proposed mechanism shown in video below: #hemepath #pathtwitter #mmsm @KirillLyapichev @sanamloghavi @KMirza @Xiaoqiong_Wang @
Daratumumab Biosimilar, Research Grade | CD38 mAb - Ushelf
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma - ScienceDirect
Understanding DARZALEX and DARZALEX FASPRO by International Myeloma Foundation - Issuu
Everything you need to know about Daratumumab and Multiple Myeloma - Curetalks
Electrophoretic patterns post daratumumab - Joanna Sheldon, Rachel D Wheeler, Ray Powles, 2018
Artifactual Kappa Light Chain Restriction of Marrow Hematogones: A Potential Diagnostic Pitfall in Minimal Residual Disease Assessment of Plasma Cell Myeloma Patients on Daratumumab - Jiang - 2020 - Cytometry Part B:
Top Performing Drug of 2021 - Darzalex (March Edition)
How to assess clinical response in multiple myeloma
Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay. | Semantic Scholar
Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma | SpringerLink
Diagnostics | Free Full-Text | Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study
